Drug Resistant Epilepsy Clinical Trial
Official title:
Role of Plasma miRNA223 and High Mobility Group Box 1(HMGB1) as Predictors of Drug Resistant Epilepsy
Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy. Early detection of the prognosis might help in guiding patients for proper management and treatment strategy. This may open the door for new drug trials.
Epilepsy is the most prevalent neurological disorders (1). Drug-resistant epilepsy (DRE) represent approximately 30% of epilepsy..DRE is defined as failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications( ASMs).The identification of circulating biomarkers for DRE could give an early idea about the prognosis and improve the choice of correct treatment. MiRNAs are small noncoding RNAs that span between 19 and 24 nucleotide bases((2).They gain biological activity through base pairing in the 30-untranslated regions of target messenger RNA (mRNA) , thereby guiding a protein complex termed the RNA-induced silencing complex (RISC) that bind to the mRNA sequence and results in either the inhibition of translational processes or the degradation of the mRNA (3). Dysregulated miRNA expression has been associated with inflammatory pathways, cell death, neuronal excitability, and synaptic reorganization, which underlie epileptogenesis (4). High- mobility group box 1(HMGB1) is a chromatin component that is physiologically attached to nuclei. However, following CNS insult, it can promptly be migrated towards cytoplasm and is discharged extracellularly. HMGB1mediates sterile neuro-inflammation evoked by epileptogenic injury and recurrent seizures(5) .HMGB1 increases in neurons, glia, and endothelial cells of the blood brain barrier (BBB) in DRE. The HMGB1 contributes to the overexpression of P-glycoprotein, a BBB protein, which is induced in DRE foci and extrudes various ASMs from the brain(6) . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05928598 -
Goals for Epilepsy Clinic Visits Trial
|
N/A | |
| Recruiting |
NCT05539287 -
Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy
|
Phase 2 | |
| Not yet recruiting |
NCT04601974 -
Lentiviral Gene Therapy for Epilepsy
|
Phase 1/Phase 2 | |
| Completed |
NCT02982824 -
Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
|
N/A | |
| Recruiting |
NCT05485558 -
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
|
Phase 2 | |
| Not yet recruiting |
NCT04553354 -
Cortical Resections in Drug Resistant Epilepsy
|
||
| Recruiting |
NCT04999046 -
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
|
N/A | |
| Recruiting |
NCT04714996 -
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
|
Phase 2 | |
| Recruiting |
NCT04839601 -
RNS System RESPONSE Study
|
N/A | |
| Recruiting |
NCT06059157 -
Epileptogenic Network Visualisation With Advanced MRI
|
N/A | |
| Recruiting |
NCT05947656 -
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
|
N/A | |
| Recruiting |
NCT05393518 -
Electroclinical Correlation of Anxiety
|
N/A | |
| Completed |
NCT03419000 -
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
|
N/A | |
| Enrolling by invitation |
NCT06341075 -
Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy
|
N/A | |
| Not yet recruiting |
NCT05527093 -
Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy
|
N/A | |
| Recruiting |
NCT05697614 -
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
|
Phase 4 | |
| Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
| Not yet recruiting |
NCT06340802 -
A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl
|
N/A | |
| Completed |
NCT03860298 -
Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy
|
N/A |